---
title: "Regenxbio Q2 FY26 swings to net income of $22.71 million; revenue climbs to $108.02 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295098388.md"
description: "Regenxbio reported a GAAP net income of $22.71 million for Q2 FY26, swinging from previous losses as revenue more than doubled to $108.02 million. This surge was driven by a $100 million AbbVie milestone payment related to NAAVIGATE dosing, which pushed license and royalty revenue to $103.84 million. Operating income reached $29.26 million, while R&D expenses decreased slightly. The company holds $105.5 million in cash and expects funding through Q4 2027."
datetime: "2026-08-06T11:21:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295098388.md)
  - [en](https://longbridge.com/en/news/295098388.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295098388.md)
generator: "portal-rs"
---

# Regenxbio Q2 FY26 swings to net income of $22.71 million; revenue climbs to $108.02 million

-   Regenxbio swung to GAAP net income of USD 22.71 million in Q2 2026 as revenue more than doubled to USD 108.02 million. \* License and royalty revenue more than doubled to USD 103.84 million, driven by a USD 100 million AbbVie milestone tied to NAAVIGATE dosing. \* R&D expense fell 5.74% to USD 56.09 million; general and administrative costs climbed 8.72% to USD 21.62 million. \* Operating income was USD 29.26 million; cost of license and royalty revenues dropped to USD 1.04 million from USD 5.21 million. \* Cash, cash equivalents and marketable securities totaled USD 105.5 million at June 30, 2026; Regenxbio expects funding into Q4 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regenxbio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-336725), on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [RGNX.US](https://longbridge.com/en/quote/RGNX.US.md)
- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)

## Related News & Research

- [REGENXBIO elects Gregory Ciongoli as director; Jean Bennett and. "Jerry" Karabelas resign](https://longbridge.com/en/news/296955594.md)
- [RegenXBio Faces RGX-121 Clinical Hold, Refocuses Pipeline](https://longbridge.com/en/news/296834397.md)
- [FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome](https://longbridge.com/en/news/296779641.md)
- [Exmar announces availability of 2026 half-year results release](https://longbridge.com/en/news/296992548.md)
- [REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli | RGNX Stock News](https://longbridge.com/en/news/296903302.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**